When the smoking cessation medication, Chantix, was trending on Twitter Monday, it quickly became apparent that it wasn’t just because the manufacturer had recalled it. Yes, the recall of the drug ...

NEW YORK (Reuters Health) - In a trial among people with a history of depression, those taking the quit-smoking aid varenicline - marketed in the U.S. as Chantix - were no more prone to depression or ...

A popular drug prescribed to help people quit smoking may pose a significantly increased risk of heart attack in users, a new study finds. The results may further complicate doctors’ and patients’ ...

The FDA is currently evaluating cases that Pfizer submitted. “A preliminary assessment reveals that many of the cases reflect new-onset of depressed mood, suicidal ideation, and changes in emotion and ...

WASHINGTON — Of the roughly 15 million Americans who tried to quit smoking in 2022, 5 in 6 failed. It’s a jarring statistic — and an indictment of the treatment options for an addiction that kills 480 ...

Kicking the habit can be hard enough, but smokers with depression face a steeper challenge. Now there’s evidence that the drug varenincline (Chantix) can help.more About half of smokers who try to ...

Pfizer, Glaxo hope FDA will remove warning on their smoking-cessation pills, after big study finds no suicide risk This April 13, 2016, photo provided by Pfizer shows Pfizer Discovery Medicinal ...

(Reuters) - U.S. health regulators on Friday allowed Pfizer Inc to remove a serious warning from the label of its smoking cessation treatment, Chantix, giving a new lease of life to the controversial ...

REP. BOB FILNER (D-CA), CHAIRMAN, HOUSE COMMITTEE ON VETERANS AFFAIRS: But this is a controlled study. This was not the last thing they could ever have to save their life; this was something to help ...

Pfizer's stop-smoking drug Chantix can lead to a small increase in cardiovascular problems such as heart attacks for patients who already have cardiovascular disease, U.S. drug regulators said on ...

WASHINGTON (AP) — The Food and Drug Administration announced Friday it will hold a public meeting in October to review the risks of psychiatric and behavioral side effects with Pfizer’s anti-smoking ...